Anti-EGFR CAR-transduced T-cell therapy - Cellular Biomedicine Group

Drug Profile

Anti-EGFR CAR-transduced T-cell therapy - Cellular Biomedicine Group

Alternative Names: Anti-EGFR CAR; CART-EGFR; CART-HER1; Chimeric-EGFR-antigen-receptor-modified-T-cells

Latest Information Update: 21 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chinese PLA General Hospital
  • Developer Cellular Biomedicine Group; Chinese PLA General Hospital
  • Class Cancer vaccines; CAR-T cell therapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 21 Aug 2017 Phase-I/II development is ongoing in China (NCT01869166)
  • 28 Sep 2015 Interim efficacy and adverse events data from a phase I/II trial in Solid tumours released by Cellular Biomedicine Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top